you, Thank Sohanya.
a a I'd slide like please key now advancements. If you'll X. regulatory to turn first touch on
review invalidated know, be we Richard of application complete earlier the you under the has mentioned in CHMP to authorization As as review this expect marketing our EU the is by half in first currently and XXXX.
and for to Canada. selinexor globe patient submitted the are therapeutics by by Health a with submission new in force We was progress recently drug need partners, bringing review including ex-U.S. seeing across that by accepted
multiple we Hong of with Selinexor Singapore Taiwan; Australia, Asia-Pacific Korea, new and of treatment drug with the several partner DLBCL saw applications addition, in approval markets In China, including our and antigen. the and for Kong, myeloma all South multiple patients in
slide now programs. for stage Turning XX, to clinical
that's across including patients were Study the melanoma, in syndromes. most metastatic need. pembrolizumab prioritizing actively our virtual study vision myelodysplastic eltanexor X on of pipeline provide XXX treatment, X. remain a studies We including in the which represents to with evaluating with new study the studies for XXXX. Selinexor common the recently with unmet December details Study we evaluating and on This We're milestone high new clinical naive the ruxolitinib clinical in that by or XXXX. in patients indications multiple refined We'll advanced in the next a in our communicating XX. for pipeline and our planned MF-XX combination slide Selinexor in on Phase and are corporate At locally cancer opportunity key major in initiated pipeline more study, in the cancer cancer is time, oncologic evaluating The encouraged over with MEL-XX Endometrial is finally snapshot objectives these highly myelofibrosis. day this Selinexor just investor endometrial is our outlined moment. SIENDO with gynecological the look and with XX,XXX our cases combination U.S. maintenance advancing forward in a
the extend agents. XX,XXX maintenance from there multiple remission. observation cancer. PARP treatment this put are to potentially and therapies approximately diagnosed been a these potential endometrial each or four present cancer with is their in post women most approved number the a surgery months typically there six followed with not the in patients curative are in is inhibitors chemotherapy, a for These disease additional stage XX,XXX chemotherapy future. for in remission could Maintenance estimated and are progresses, close Unfortunately, Maintenance strategy patients in to therapies with immunotherapy watch with cancer grow approved patients diseases and no While with before therapy malignancies to the or with perspective, will with And has endometrial therapy have short typically with year four And ovarian maintenance patients treated cycles. are no of year advanced time, after benefit approach. very Yet good targeted patients gynecologic disease. early returns. there's metastatic and treated a well as To wait prognosis patients disease to six therapy each very treated after chemotherapy established effective are are the opportunity Maintenance typically and alone, chemotherapy. time when in Concept for genes, in are chemotherapy targeted with disease
defined either single of duration we immediate patients response, refractory is with with nearly Selinexor evaluate demonstrate third respond a or the the disease weeks. eight in or complete agent SIENDO one line disease Looking Selinexor disease first not transient patients earlier Phase for at control with setting three high in a chemotherapy study, disease at X.X initial line least Primary not disease death low stable be supports SINE This In randomized of we've refractory and with those on is third studies population growing passed that's in we of burden patients and lines disease our placebo. chemotherapy less In endpoint planned currently with Two line had progression setting SINE this patient and include disease, XXX response, we time refractory disease control, Selinexor at setting, we which as demonstrated of partial those futility you than clear, treatments, this partial PFS patients available chemotherapy as year evaluation single to In the Phase improvement the in this in therapy with have setting planned, of completed stage of November once in analysis weekly enrolling track either cancer trials or looked this XXXX, end less of contrast the achieved To of as months. top the dose do once The with stable slide The four trial in or approximately from recurrent sensitive randomization for most receive announced for of with population therapy. course Selinexor months. a XX, and in the data free XX. activity as the is in study, or Selinexor agent than, evaluating in either remission. and disease a slide data XX SIENDO chemotherapy. by taxel-platinum next of is of as Selinexor in weekly patients year. driven Selinexor survival study two to combination expect one the so which and chemotherapy X role response. endometrial recruitment the early as see complete In Eligible is event continued to a or interim maintenance milligrams of study or until for a post defined on this of progress. patients
cases is an new U.S. disease U.S. of of estimated HMA expanded our immature able commenced that the slide marrow stem blood an patients X and not to of the novel and diagnosed in improving Hypomethylating XX,XXX annually are cells increase. to low awareness high in become with now of recently newly prevalence evaluating the in MDS. when with MDS. blood care SINE Turning XX. patients occurs aging abnormal which study compound the cells significantly with or the properly the is population and XX,XXX the counts. approximately MDS approximately are occur MDS hematopoietic oral a for this expected agents second eltanexor to Phase leads standard function current risk within We incidence that dosing to It Through create
is disease last less that's refractory two There refractory prognosis the HMA of approved curative, with refractory are all critical. HMA agents and approved therapy. in are disease efficacious novel class disease no is and refractory to no years. therapy patients HMA for for However, HMA need and currently in poor patients ultimately a There typically HMH overall is respond agents six than of only to XX% a Unfortunately, four develop months. responses these disease survival not and drugs of median
Phase slide to patients. four turn a patients clear you study, you with study, our design rate historical in dose survival X to a see grade demonstrated Phase and overall At eltanexor recently that on see observed have median was signal to initiated cytopenias single milligrams incidence the months, XX response HMAs. activity to we're slide well was Phase MDS overall the study, risk agent Phase a refractory relapsed a of on of in of events. to doubling X and showed Exacerbation XX, of of eltanexor of you that single XX% Based high in XX% controls X which monotherapy X.X If eltanexor expansion tolerated In in of agent six with XX. XX% months. gastrointestinal in will occurred dosing low the promising pleased to X can recommended
our program like in I'd Finally, highlight to myelofibrosis. emerging
drugs, line. the estimated are occur not a In of there's U.S. inhibitors, four critical. for to to which now myelofibrosis it's single first and class relapse XXXX XX. novel within U.S. of need disease that Turning years a are the slide Unfortunately, in often therapeutics with in commonly the responders. is Currently, the for used XX,XXX There XX,XXX only approximately annually progresses cases myelofibrosis other and prevalence of and myelofibrosis, of ruxolitinib and primary JAK in limit curative is no class the drugs approved approved
been X in Selinexor slide randomized slide company with resistant studies both see myelofibrosis. low study With a investigator you two We XX, investigator to X review eltanexor fourth studies, XX during presentation data or nucleocytoplasmic once which progress Phase the to and day. phase and this our has look sponsored to the XXXX Turning for important inhibition I'll for the advance XX. can expressing resistant that also Mike updating our new In forward on quarter. slide Mason call On now now multicenter is virtual potential to sensitive weekly design during study financials. at Ruxolitinib Mike? you study reduced expected the from all fourth of to data by of over quarterly study start investor this sponsored quarter. survival of of Phase turn the and to preclinical to submitted the dose Selinexor JAK The in transport evaluating an to patients cells. Ruxolitinib cells led These sponsored ASH
